Lataa...
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well understood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled “Co-opti...
Tallennettuna:
| Julkaisussa: | Chin J Cancer |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5124233/ https://ncbi.nlm.nih.gov/pubmed/27887628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0162-7 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|